Background and aims: The management of patients treated for hepatitis C recurrence after liver transplantation and not achieving virological response following treatment with interferon plus ribavirin is controversial. Methods: A retrospective analysis of the outcomes of 70 patients non-responders to antiviral treatment after liver transplantation was performed. Twenty-one patients (30.0%; Group A) were treated for ≤12 months and 49 (70.0%; Group B) for more than 12 months. Results: The 2 groups were comparable for main demographic, clinical and pathological variables. Median duration of antiviral treatment was 8.2 months in Group A and 33.4 months in Group B. No patient achieved a complete virological response. The 5-year patient hepatitis C-related survival rate was 49.2% in Group A and 88.3% in Group B (P = 0.002), while the 5-year graft survival rate was 49.2% in Group A and 85.9% in Group B (P = 0.007). The median yearly fibrosis progression rate was 1.21 per year in Group A and 0.40 per year in Group B (P = 0.001). Conclusions: Prolonged antiviral treatment showed an overall beneficial effect in transplanted patients with a recurrent hepatitis C infection and not responding to conventional therapy. The treatment should be continued as long as it is permitted, in order to improve clinical and histological outcomes.

Long-term antiviral treatment for recurrent hepatitis C after liver transplantation / Bertuzzo, VALENTINA ROSA; Cescon, Matteo; Morelli, M. C.; DI GIOIA, Paolo; Tame', Mariarosa; Lorenzini, S.; Andreone, Pietro; Ercolani, Giorgio; DEL GAUDIO, Massimo; Ravaioli, Matteo; Cucchetti, Alessandro; Dazzi, Alessandro; D'Errico, Antonietta; Pinna, ANTONIO DANIELE. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 44:10(2012), pp. 861-867. [10.1016/j.dld.2012.06.013]

Long-term antiviral treatment for recurrent hepatitis C after liver transplantation

ANDREONE, PIETRO;DAZZI, ALESSANDRO;PINNA, ANTONIO DANIELE
2012

Abstract

Background and aims: The management of patients treated for hepatitis C recurrence after liver transplantation and not achieving virological response following treatment with interferon plus ribavirin is controversial. Methods: A retrospective analysis of the outcomes of 70 patients non-responders to antiviral treatment after liver transplantation was performed. Twenty-one patients (30.0%; Group A) were treated for ≤12 months and 49 (70.0%; Group B) for more than 12 months. Results: The 2 groups were comparable for main demographic, clinical and pathological variables. Median duration of antiviral treatment was 8.2 months in Group A and 33.4 months in Group B. No patient achieved a complete virological response. The 5-year patient hepatitis C-related survival rate was 49.2% in Group A and 88.3% in Group B (P = 0.002), while the 5-year graft survival rate was 49.2% in Group A and 85.9% in Group B (P = 0.007). The median yearly fibrosis progression rate was 1.21 per year in Group A and 0.40 per year in Group B (P = 0.001). Conclusions: Prolonged antiviral treatment showed an overall beneficial effect in transplanted patients with a recurrent hepatitis C infection and not responding to conventional therapy. The treatment should be continued as long as it is permitted, in order to improve clinical and histological outcomes.
2012
44
10
861
867
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation / Bertuzzo, VALENTINA ROSA; Cescon, Matteo; Morelli, M. C.; DI GIOIA, Paolo; Tame', Mariarosa; Lorenzini, S.; Andreone, Pietro; Ercolani, Giorgio; DEL GAUDIO, Massimo; Ravaioli, Matteo; Cucchetti, Alessandro; Dazzi, Alessandro; D'Errico, Antonietta; Pinna, ANTONIO DANIELE. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 44:10(2012), pp. 861-867. [10.1016/j.dld.2012.06.013]
Bertuzzo, VALENTINA ROSA; Cescon, Matteo; Morelli, M. C.; DI GIOIA, Paolo; Tame', Mariarosa; Lorenzini, S.; Andreone, Pietro; Ercolani, Giorgio; DEL GAUDIO, Massimo; Ravaioli, Matteo; Cucchetti, Alessandro; Dazzi, Alessandro; D'Errico, Antonietta; Pinna, ANTONIO DANIELE
File in questo prodotto:
File Dimensione Formato  
2012 (Dig Liv Dis) Bertuzzo - Long term AVT in HCV.pdf

Accesso riservato

Dimensione 276.17 kB
Formato Adobe PDF
276.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237242
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact